Evaxion Biotech A/S (NASDAQ: EVAX)
$3.09
-0.0592 ( -1.88% ) 42.9K
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
Market Data
Open
$3.09
Previous close
$3.15
Volume
42.9K
Market cap
$16.99M
Day range
$2.82 - $3.23
52 week range
$2.26 - $13.82
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 2 | Dec 08, 2023 |
6-k | Quarterly Reports | 2 | Nov 28, 2023 |
6-k | Quarterly Reports | 2 | Nov 17, 2023 |
6-k | Quarterly Reports | 2 | Nov 15, 2023 |
6-k | Quarterly Reports | 2 | Nov 06, 2023 |
6-k | Quarterly Reports | 2 | Oct 31, 2023 |
6-k | Quarterly Reports | 2 | Oct 26, 2023 |
6-k | Quarterly Reports | 2 | Oct 13, 2023 |
6-k | Quarterly Reports | 3 | Oct 05, 2023 |
6-k | Quarterly Reports | 5 | Sep 27, 2023 |